The OPUS study demonstrated that addition of cetuximab to @-fluorouracil , folinic acid and oxaliplatin ( FOLFOX@ ) significantly improved objective response and progression-free survival ( PFS ) in the first-line treatment of patients with KRAS exon @ wild-type metastatic colorectal cancer ( mCRC ) .